| __timestamp | Alnylam Pharmaceuticals, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 44820000 |
| Thursday, January 1, 2015 | 60610000 | 82080000 |
| Friday, January 1, 2016 | 89354000 | 97130000 |
| Sunday, January 1, 2017 | 199365000 | 121271000 |
| Monday, January 1, 2018 | 382359000 | 153548000 |
| Tuesday, January 1, 2019 | 479005000 | 202541000 |
| Wednesday, January 1, 2020 | 588420000 | 245164000 |
| Friday, January 1, 2021 | 620639000 | 285773000 |
| Saturday, January 1, 2022 | 770658000 | 325998000 |
| Sunday, January 1, 2023 | 795646000 | 332540000 |
| Monday, January 1, 2024 | 975526000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Alnylam Pharmaceuticals, Inc. and PTC Therapeutics, Inc. have been at the forefront of this challenge since 2014. Over the past decade, Alnylam's SG&A expenses have surged by approximately 1,700%, reflecting its aggressive expansion strategy. In contrast, PTC Therapeutics has maintained a more conservative growth, with a 640% increase in the same period.
By 2023, Alnylam's SG&A expenses were nearly 2.4 times higher than PTC's, indicating a significant divergence in their operational strategies. This data highlights the contrasting approaches of these two companies in managing their operational costs, with Alnylam focusing on rapid scaling and PTC on steady growth. Understanding these trends provides valuable insights into their strategic priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.